HSA Warns Against Taking "Jianbu Huqian Wan" - An Adulterated Product Found To Contain Undeclared Potent Western Medicinal Ingredients, Singapure
This product was reported to HSA's Vigilance Branch by a member of the public who became suspicious of the product, when her mother experienced rapid relief from body aches soon after consuming the product over a short period of time. Her mother had also suffered adverse effects as a result of taking the illegal product.
About the Product
"JianBu HuQian Wan" is an illegal adulterated product which has not been approved by HSA. The product was bought from overseas and is indicated to treat joint pain, muscle aches and weak limbs.
The illegal product is presented in a yellow and green outer box, which contained a white bottle with red and white capsules. The product's label carries an invalid Malaysian Product Registration Number "MAL05121196T". The label also contains inaccurate information regarding its manufacturer and distributor.
About the Adverse Reaction
HSA's investigation revealed that the 70 year-old elderly female patient had poor diabetic control with increased glucose levels as a result of taking the product. The patient was also reported to have developed varicose vein with blood clots, rapid weight gain and increased appetite after starting the product. These symptoms are similar to the adverse effects caused by the prolonged use of the corticosteroid, dexamethasone. The patient has since stopped consuming the product and is recovering from the adverse effects.
Unsupervised and long-term use of dexamethasone, which is an anti-inflammatory medicine, can cause harmful effects such as increased blood glucose level, high blood pressure, muscle damage, mental disorders and weak bones leading to osteoporosis. The adverse effects of chlorpheniramine, an antihistamine commonly found in cold medications, include drowsiness, confusion, and urinary retention.
Dexamethasone and chlorpheniramine are potent medicinal products that should be prescribed by healthcare professionals. Patients taking these products need to be under medical supervision. Dexamethasone and chlorpheniramine are substances controlled under the Poisons Act. It is an offence for an unlicensed person to import, sell or possess for sale any product containing these substances. Anyone found guilty of an offence under the Poisons Act is liable to a fine of up to $10,000 and/or imprisonment for a term of up to two years
HSA strongly advises consumers who have purchased this product not to consume it. If consumers have taken this product, they should seek medical attention if they feel unwell or are concerned about their health.
Consumers are advised to be wary of traditional and complementary medicines that show quick and miraculous therapeutic effects, especially if these products are bought from unreliable sources and claim to treat serious conditions.
If you are aware of the product being sold illegally, please provide information to assist our investigation by contacting HSA's Enforcement Branch by email email@example.com.
Health Sciences Authority
There are no references listed for this article.
Visit our Complementary Medicine / Alternative Medicine category page for the latest news on this subject, or sign up to our newsletter to receive the latest updates on Complementary Medicine / Alternative Medicine.
Please use one of the following formats to cite this article in your essay, paper or report:
Authority, Health Sciences. "HSA Warns Against Taking "Jianbu Huqian Wan" - An Adulterated Product Found To Contain Undeclared Potent Western Medicinal Ingredients, Singapure." Medical News Today. MediLexicon, Intl., 15 Dec. 2010. Web.
22 Oct. 2016. <http://www.medicalnewstoday.com/releases/211396.php>
Authority, H. (2010, December 15). "HSA Warns Against Taking "Jianbu Huqian Wan" - An Adulterated Product Found To Contain Undeclared Potent Western Medicinal Ingredients, Singapure." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.